The Venture Codex Logo

The Venture Codex

Real Ventures

3 Place Ville-Marie, Suite 400, Montréal, QC, H3B 2E3, Canada

Overview

Real Ventures is an early-stage venture firm focused on serving daring entrepreneurs with the ambition to create successful, global companies. Since 2007, Real Ventures has dedicated itself to building the Canadian startup ecosystem on the belief that people, not money, build game-changing companies. Real Ventures provides stage-specific guidance, mentorship, and access to networks and resources to fast-track founders’ personal and company growth. Real Ventures manages $325 million across five funds and its active portfolio of 100+ companies is currently valued at $10 billion. www.realventures.com

Total investments
147
Lead investments
29
Investments · 12mo
3
Active investors
8

Sector focus

  • Finance
  • Financial Services
  • Incubators
  • Venture Capital
Visit website

Investment portfolio

  • Nord Quantique

    Participated · Equity · May 2026

    Nord Quantique develops a hardware-efficient quantum computing architecture that embeds error correction at the individual qubit level using superconducting bosonic codes. Its design targets a 1:1 logical-to-physical qubit ratio to reduce physical qubit overhead and capital requirements compared with legacy quantum systems. The architecture is said to enable faster clock speeds and data-center-compatible scaling. The company is led by co-founder and CEO Julien Camirand Lemyre and is based in Sherbrooke, Quebec. Financially, Nord Quantique recently raised $30M in growth equity at a $1.4B valuation, and previously secured $16M from the Canadian Quantum Champions Program and $5M in active DARPA Stage B funding with potential for further DARPA funding. The company plans to use recent proceeds to scale engineering operations and advance toward commercially viable, fault-tolerant quantum computers by 2030.

  • SPARK Microsystems

    Led · Series B · Mar 2026

    SPARK Microsystems designs and develops next-generation short-range wireless communication devices using its patented LE-UWB™ technology, targeting consumer, industrial and medical applications. The company emphasizes ultra-low-power, high-speed connectivity with strong interference robustness and very low latency, and its technology supports ranging and positioning as well as data communication. SPARK cites use cases including wearables, peripherals, tags, sensors and other IoT-connected devices. The firm participates in Canada’s FABrIC initiative and is collaborating with Motsai, Bittele Electronics and C2MI for design, prototyping and manufacturing. SPARK was awarded a CAD $1 million FABrIC grant from the Government of Canada to support product development under the IoT Device Challenge. The article does not provide revenue, user, or valuation metrics.

  • Tilt

    Participated · Seed · Sep 2025

    Tilt provides a software platform that enables financial advisors, TAMPs, and RIAs to create customized indices at scale through an AI-driven thematic research workflow. The system’s embedding engine continuously ingests and scores data from SEC filings, news articles, and social media, surfacing both consensus and emerging themes for portfolio construction. Portfolios can be launched with no account minimums, rebalanced at higher frequencies, and priced starting at just three basis points, bringing institutional-grade direct indexing to a broader market. Real-time tax-optimization is built into the service, allowing advisors to meet growing client demand for personalized and tax-efficient investing. With its official launch scheduled behind a waitlist on September 22 at Portage’s Confluence event, the company plans to roll out a suite of tools that deepen advisor–client collaboration. Proceeds from the seed round will expand engineering and go-to-market teams, enhance the tax engine, and scale integrations with fintech platforms and advisory firms.

  • Blumind

    Participated · Series A · Apr 2025

    Blumind is a Canadian deep‑tech AI start‑up based in Ottawa developing ultra‑low‑power all‑analog AI compute semiconductors, software and data‑driven system solutions. Its AMPL™ analog AI technology is designed to dramatically reduce power consumption and latency for always‑on AI applications; Blumind says its products consume up to 1000x lower power than available alternatives and use standard CMOS process technology. The company is commercializing a first‑generation AI processor for processing real‑time sensor data and is accelerating design of next‑generation analog AI chips for vision and large language model inferencing. Blumind plans to expand engineering and development teams, accelerate chip design and production, and support existing tier‑1 lead customers while establishing strategic partnerships. The company recently closed a C$20M Series A and is keeping the round open as it engages with strategic investors to further scale operations and commercialization efforts. CEO and co‑founder Niraj Mathur said the funding will help rapidly scale the business and bring efficient, low‑latency AI to the edge.

  • Nomic

    Participated · Series B · Sep 2024

    Nomic develops the proprietary nELISA platform, enabling massive multiplexing, full quantification, and cost-efficient protein profiling. The platform currently offers a comprehensive solution for inflammation research and high-throughput quantification of hundreds of secreted proteins. Nomic serves over 75 customers across top-10 pharma, innovative biotechs, and research institutes and has collectively profiled more than 400,000 samples. To meet surging demand the company has built industrial-scale facilities offering high throughput and fast turnaround for protein profiling services. With new capital Nomic plans to expand commercial operations, further advance the nELISA platform, and broaden its offerings to cover proteins across the entire proteome. Leadership cited in the article includes CEO and co‑founder Milad Dagher and board member Byron Hewett. Nomic Bio is building the nELISA, a next-generation ELISA platform that leverages DNA nanotechnology, spectral multiplexing, and automation to enable massively scalable, multiplexed protein quantification. The nELISA is designed to deliver high throughput and cost-efficiency while maintaining the sensitivity and specificity of traditional ELISAs and to integrate into existing biological workflows. Nomic has worked with select partners across the pharmaceutical and biotech industry, from mid-sized biotechs to top-ten pharma, to advance drug discovery. The company will use new capital to grow teams in Montreal and Boston and to expand access to the platform. Planned operational goals include increasing profiling capacity to 100,000 samples a quarter by Q2 2022, scaling the nELISA to 500 on-boarded proteins, and beginning development of new modalities such as post-translational modification identification. The company has raised over US$21 million to date following its recent financing.

Team